Ultrasonographic detection of hepatocellular carcinoma: correlation of preoperative ultrasonography and resected liver pathology

2006 ◽  
Vol 61 (2) ◽  
pp. 191-197 ◽  
Author(s):  
J.H. Lim ◽  
S.H. Kim ◽  
W.J. Lee ◽  
D. Choi ◽  
S.H. Kim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Pathology ◽  
Resected Liver ◽  
Preoperative Ultrasonography

scholarly journals Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal

2020 ◽  
Vol 21 (20) ◽  
pp. 7473
Author(s):  
Alip Ghosh ◽  
Sara Romani ◽  
Shyam Kottilil ◽  
Bhawna Poonia
Keyword(s):  
Hepatocellular Carcinoma ◽  
Immune System ◽  
Virologic Response ◽  
Viral Clearance ◽  
Liver Pathology ◽  
Direct Acting Antiviral ◽  
Chronic Hcv ◽  
Direct Acting ◽  
Immune Defects ◽  
The Impact

Chronic HCV (CHC) infection is the only chronic viral infection for which curative treatments have been discovered. These direct acting antiviral (DAA) agents target specific steps in the viral replication cycle with remarkable efficacy and result in sustained virologic response (SVR) or cure in high (>95%) proportions of patients. These treatments became available 6–7 years ago and it is estimated that their real impact on HCV related morbidity, including outcomes such as cirrhosis and hepatocellular carcinoma (HCC), will not be known for the next decade or so. The immune system of a chronically infected patient is severely dysregulated and questions remain regarding the immune system’s capacity in limiting liver pathology in a cured individual. Another important consequence of impaired immunity in patients cleared of HCV with DAA will be the inability to generate protective immunity against possible re-infection, necessitating retreatments or developing a prophylactic vaccine. Thus, the impact of viral clearance on restoring immune homeostasis is being investigated by many groups. Among the important questions that need to be answered are how much the immune system normalizes with cure, how long after viral clearance this recalibration occurs, what are the consequences of persisting immune defects for protection from re-infection in vulnerable populations, and does viral clearance reduce liver pathology and the risk of developing hepatocellular carcinoma in individuals cured with these agents. Here, we review the recent literature that describes the defects present in various lymphocyte populations in a CHC patient and their status after viral clearance using DAA treatments.

Doxorubicin Drug-Eluting Embolic Chemoembolization of Hepatocellular Carcinoma: Study of Midterm Doxorubicin Delivery in Resected Liver Specimens

2017 ◽  
Vol 28 (6) ◽  
pp. 804-810 ◽  
Author(s):  
Hadrien D’inca ◽  
Olivier Piot ◽  
Marie-Danièle Diebold ◽  
Tullio Piardi ◽  
Claude Marcus ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Resected Liver ◽  
Drug Eluting ◽  
Doxorubicin Delivery

scholarly journals Pathologic and Radiographic Studies of Intrahepatic Metastasis Hepatocellular Carcinoma; The Role of Efferent Vessels

HPB Surgery ◽  
1996 ◽  
Vol 10 (2) ◽  
pp. 97-104 ◽  
Author(s):  
Akihiro Toyosaka ◽  
Eizo Okamoto ◽  
Masao Mitsunobu ◽  
Takeshi Oriyama ◽  
Norio Nakao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Portal Vein ◽  
Direct Injection ◽  
Statistical Correlation ◽  
Intrahepatic Metastasis ◽  
Hepatic Veins ◽  
Tumor Spread ◽  
Vein Thrombosis ◽  
Resected Liver

The efferent vessel of hepatocellular carcinoma (HCC) and the mechanism and pathogenesis of the high frequency of intrahepatic metastasis in HCC has not yet been clarified. Three hundred ninety-three resected specimens of HCC were examined for tumor thrombosis in the portal vein and the hepatic vein: 231 tumors ≤5 cm in diameter were examined for the relationship between mode of tumor spread and tumor size. Efferent vessels in HCC were identified by direct injection of radiopaque material into the tumor in 23 resected liver specimens and by percutaneous infusion of radiopaque media into tumor nodules in 8 patients. The mode of tumor spread in HCC progressed from capsular invasion to extracapsular invasion, then to vascular invasion, and finally to intrahepatic metastasis. There was a strong statistical correlation between the presence of intrahepatic metastasis and portal vein thrombosis (p<0.05, R=0.998). Radiopaque material injected directly into 23 resected tumors entered only the portal vein in 17 tumors and into both the portal and hepatic veins in 6 tumors. In all 8 patients with unresectable lesions, radiopaque media injected percutaneously into tumor nodules flowed only into the portal vein. These findings suggest that intrahepatic invasion by HCC may occur through the portal vein as an efferent tumor vessel.

Glypican-3 as a Useful Diagnostic Marker That Distinguishes Hepatocellular Carcinoma From Benign Hepatocellular Mass Lesions

2008 ◽  
Vol 132 (11) ◽  
pp. 1723-1728 ◽  
Author(s):  
Hanlin L. Wang ◽  
Florencia Anatelli ◽  
Qihui“Jim” Zhai ◽  
Brian Adley ◽  
Shang-Tian Chuang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatocellular Adenoma ◽  
Diagnostic Value ◽  
Small Subset ◽  
Resected Liver ◽  
Background Staining ◽  
Gpc3 Expression ◽  
Regenerative Nodules ◽  
A Cell ◽  
Mass Lesions

Abstract Context.—Histopathologic distinction between hepatocellular carcinoma (HCC) and benign hepatocellular mass lesions, particularly hepatocellular adenoma, can sometimes be challenging. The currently available ancillary tools are suboptimal in terms of sensitivity and specificity. Objective.—To further characterize the diagnostic value of glypican-3 (GPC3), a cell surface proteoglycan that has recently been shown to be overexpressed in HCC, in the distinction between HCC and benign hepatocellular mass lesions. Design.—A total of 221 surgically resected liver specimens were subjected to immunohistochemical staining using a monoclonal antibody specific for GPC3. These included 111 HCCs, 48 hepatocellular adenomas, 30 focal nodular hyperplasias, and 32 large regenerative nodules in the background of cirrhosis. Results.—Cytoplasmic, membranous, and canalicular staining for GPC3 was detected in 84 (75.7%) of the 111 HCCs, among which, 61 (72.6%) of the 84 cases exhibited diffuse immunoreactivity. In contrast, none of the 110 cases of hepatocellular adenoma, focal nodular hyperplasia, and large regenerative nodule showed detectable GPC3 staining. Focal GPC3 immunoreactivity was detected in cirrhotic nodules in 11 (16.4%) of 67 HCC cases with a cirrhotic background, but no background staining was observed in the remaining 44 HCCs without cirrhosis. GPC3 expression in HCCs did not correlate with the size, differentiation, or stage of the tumors; the presence or absence of cirrhotic background; or the underlying etiologies. Conclusions.—GPC3 is a specific immunomarker for HCC that can be used to distinguish HCC from benign hepatocellular mass lesions, particularly hepatocellular adenoma. However, the diagnosis of HCC should not rely entirely on positive GPC3 immunostaining because focal immunoreactivity can be detected in a small subset of cirrhotic nodules. In addition, GPC3 expression in HCC can also be focal, and thus, the lack of GPC3 staining does not exclude the diagnosis of HCC.

Changes in Expression of Bile Canalicular CD10 and Sinusoidal CD105 (Endoglin) in Peritumoral Hepatic Tissue

2009 ◽  
Vol 95 (4) ◽  
pp. 495-500 ◽  
Author(s):  
Toshitsugu Nakamura
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Tumor Growth ◽  
Expression Patterns ◽  
Metastatic Carcinoma ◽  
Hepatic Tissue ◽  
Bile Canaliculi ◽  
Metastatic Tumors ◽  
Phenotypic Changes ◽  
Resected Liver

Aims and background Hepatic tissues, including bile canaliculi and sinusoids, around primary or metastatic tumors are destructed and regenerate associated with tumor growth, and may show some phenotypic changes. The present study was undertaken to examine the expression of CD10 in bile canaliculi [CD10(BC)] and CD105 (endoglin) along hepatic sinusoids [CD105(HS)] in peritumoral hepatic tissue (PTH). Methods Fifty samples of resected liver bearing hepatocellular carcinoma (HCC) or metastatic carcinoma were immunostained for CD10 and CD105. The immunoreactivity for CD10(BC) and CD105(HS) in the background hepatic tissue of tumors and PTH was scored separately. Results CD10(BC) was moderately or markedly expressed in the background hepatic tissue without chronic hepatitis or cirrhosis in most of the cases, and was significantly downregulated in chronic hepatitis and cirrhosis. CD105(HS) was negative or minimally positive in most of the cases of hepatic tissue bearing metastatic carcinoma, and showed a significant increase in chronic hepatitis and cirrhosis. Compared with the background, PTH revealed significantly decreased CD10(BC) staining irrespective of HCC or metastatic carcinoma, and showed belt-like CD105(HS) expression in 66.7% of the cases of metastatic carcinoma and in 88.6% of those with HCC. Conclusions These data indicate that the expression patterns of CD10(BC) and CD105(HS) in PTH are similar to those in chronic hepatitis and cirrhosis, which may be caused by persistent injury and resultant regeneration of hepatic tissue.

scholarly journals Metastatic Fibrolamellar Hepatocellular Carcinoma to the Pancreas

2015 ◽  
Vol 9 (2) ◽  
pp. 266-271 ◽  
Author(s):  
Nicolas A. Villa ◽  
Rahul Pannala ◽  
Douglas O. Faigel ◽  
Danielle J. Haakinson ◽  
Nitin Katariya ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Lymph Nodes ◽  
Primary Resection ◽  
High Rate ◽  
Fibrolamellar Hepatocellular Carcinoma ◽  
Regional Lymph Nodes ◽  
Underlying Liver Disease ◽  
Liver Recurrence ◽  
Resected Liver

Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare variant of hepatocellular carcinoma, usually presenting in the younger population (<40 years) without underlying liver disease. Although it has a better prognosis than hepatocellular carcinoma, it has a high rate of recurrence months to years after primary resection. While sites of recurrence usually involve the liver, regional lymph nodes, peritoneum, and lung, metastasis to the pancreas is extremely rare, with only 2 other cases reported in the literature. We present the case of a 46-year-old patient with metastatic FL-HCC to the pancreas 30 years after diagnosis and 26 years since his last resected liver recurrence.

scholarly journals Intrahepatic splenosis mimicking hepatocellular carcinoma

2021 ◽  
Vol 25 (4) ◽  
pp. 115-121
Author(s):  
B. M. Medvedeva ◽  
A. B. Lukianchenko ◽  
K. A. Romanova ◽  
E. A. Moroz ◽  
A. N. Polyakov
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Pancreatitis ◽  
Clinical Case ◽  
Definitive Diagnosis ◽  
Histopathological Analysis ◽  
Mri Imaging ◽  
Resected Liver ◽  
History Of ◽  
Intrahepatic Splenosis

We present a rare clinical case of a 37-year-old man who had intrahepatic splenosis (IHS) mimics hepatocellular carcinoma on CT/MRI imaging. The patient with a history of splenectomy 14 years ago had no specific complains and the lesion was found incidentally during follow up imaging for the chronic pancreatitis. Definitive diagnosis of IHS was possible with post-operative histopathological analysis of the resected liver.

Sign in / Sign up

Export Citation Format

Share Document